Alexion Pharmaceuticals has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion to extend the approved indication of Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) to patients who are anti-acetylcholine receptor (AChR) antibody-positive,…
News
News
Researchers Gain Insight Into How Myasthenia Gravis Antibodies Destroy Receptor Vital to Movement
University of Southern California researchers have gained insight into how antibodies connected with a disease known as myasthenia gravis destroy a receptor crucial to movement. Their findings may give scientists clues about how to prevent the disease. The study, “Structural insights into the molecular mechanisms of…
Recent Posts
- Accepting a challenge, because I want to be who I choose to be
- Late-stage trial of claseprubart will aim to confirm drug’s benefits for gMG
- Learning how to manage fear in life with myasthenia gravis
- Vyvgart may offer IVIG alternative for people with hard-to-control gMG
- Agency backs NHS coverage of Rystiggo for hard-to-treat gMG